Close Menu

NEW YORK (GenomeWeb) – Cancer patients with a certain rare genetic variant may be more susceptible to developing treatment-induced cardiomyopathy, according to a new study.

While new cancer treatments have led to improved survival for many patients, they often come with side effects. Anthracyclines, which are used to treat both solid and hematological cancers, are linked to an increased risk of cardiotoxicity, for example, especially when combined with other drugs likes trastuzumab.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Jul
23

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.